The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials. The United States Food and Drug Administration has granted emergency use authori...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincent Peyko, Helena Ladd, Anthony Cutrona
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2020/8811798
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850156977766793216
author Vincent Peyko
Helena Ladd
Anthony Cutrona
author_facet Vincent Peyko
Helena Ladd
Anthony Cutrona
author_sort Vincent Peyko
collection DOAJ
description Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials. The United States Food and Drug Administration has granted emergency use authorization for remdesivir. This emergency use authorization does not recommend the use of remdesivir in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min unless the benefits outweigh the risks. To date, there are no studies and scant information in the literature evaluating remdesivir utilization in patients with eGFR less than 30 mL/min or receiving hemodialysis. With little utilization data for patients with acute or chronic kidney injury, remdesivir may not be considered, leaving this patient population without the opportunity of a potentially beneficial treatment option. We present a case of one patient with eGFR less than 30 mL/min that required hemodialysis in which remdesivir was safely initiated, with therapy completed without any serious adverse events.
format Article
id doaj-art-330e54dd74de4aa583d04bad36cf87ec
institution OA Journals
issn 2090-6625
2090-6633
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Infectious Diseases
spelling doaj-art-330e54dd74de4aa583d04bad36cf87ec2025-08-20T02:24:18ZengWileyCase Reports in Infectious Diseases2090-66252090-66332020-01-01202010.1155/2020/88117988811798The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring HemodialysisVincent Peyko0Helena Ladd1Anthony Cutrona2Mercy Health–St Elizabeth Boardman Hospital, Department of Pharmacy, 8401 Market St., Boardman, Youngstown, OH 44512, USAMercy Health–St Elizabeth Boardman Hospital, Department of Pharmacy, 8401 Market St., Boardman, Youngstown, OH 44512, USANEO Infectious Diseases Associates, 540 Parmalee Ave., Ste. 610, Youngstown, OH 44510, USARemdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials. The United States Food and Drug Administration has granted emergency use authorization for remdesivir. This emergency use authorization does not recommend the use of remdesivir in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min unless the benefits outweigh the risks. To date, there are no studies and scant information in the literature evaluating remdesivir utilization in patients with eGFR less than 30 mL/min or receiving hemodialysis. With little utilization data for patients with acute or chronic kidney injury, remdesivir may not be considered, leaving this patient population without the opportunity of a potentially beneficial treatment option. We present a case of one patient with eGFR less than 30 mL/min that required hemodialysis in which remdesivir was safely initiated, with therapy completed without any serious adverse events.http://dx.doi.org/10.1155/2020/8811798
spellingShingle Vincent Peyko
Helena Ladd
Anthony Cutrona
The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
Case Reports in Infectious Diseases
title The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
title_full The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
title_fullStr The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
title_full_unstemmed The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
title_short The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
title_sort safe administration of remdesivir in a patient with acute kidney injury requiring hemodialysis
url http://dx.doi.org/10.1155/2020/8811798
work_keys_str_mv AT vincentpeyko thesafeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis
AT helenaladd thesafeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis
AT anthonycutrona thesafeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis
AT vincentpeyko safeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis
AT helenaladd safeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis
AT anthonycutrona safeadministrationofremdesivirinapatientwithacutekidneyinjuryrequiringhemodialysis